ATE113947T1 - 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. - Google Patents

3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.

Info

Publication number
ATE113947T1
ATE113947T1 AT91909389T AT91909389T ATE113947T1 AT E113947 T1 ATE113947 T1 AT E113947T1 AT 91909389 T AT91909389 T AT 91909389T AT 91909389 T AT91909389 T AT 91909389T AT E113947 T1 ATE113947 T1 AT E113947T1
Authority
AT
Austria
Prior art keywords
pct
alkyl
compounds
arylquinuclidines
amino
Prior art date
Application number
AT91909389T
Other languages
English (en)
Inventor
John A Lowe Iii
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE113947T1 publication Critical patent/ATE113947T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT91909389T 1990-06-01 1991-04-25 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. ATE113947T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53252590A 1990-06-01 1990-06-01

Publications (1)

Publication Number Publication Date
ATE113947T1 true ATE113947T1 (de) 1994-11-15

Family

ID=24122165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909389T ATE113947T1 (de) 1990-06-01 1991-04-25 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.

Country Status (18)

Country Link
US (1) US5451586A (de)
EP (1) EP0532527B1 (de)
JP (1) JPH072740B2 (de)
KR (1) KR930700499A (de)
AT (1) ATE113947T1 (de)
AU (1) AU648317B2 (de)
CA (1) CA2084193C (de)
DE (1) DE69105131T2 (de)
DK (1) DK0532527T3 (de)
ES (1) ES2063507T3 (de)
FI (1) FI113654B (de)
HU (1) HUT62891A (de)
IE (1) IE911856A1 (de)
IL (1) IL98259A0 (de)
NO (1) NO924612L (de)
PT (1) PT97771A (de)
WO (1) WO1991018899A1 (de)
ZA (1) ZA914134B (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69106365T2 (de) * 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
WO1992020661A1 (en) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
DE9290063U1 (de) * 1991-05-31 1994-02-24 Pfizer Inc., New York, N.Y. Chinuclidin-Derivate
BR9206161A (pt) * 1991-06-20 1995-10-31 Pfizer Derivados fluoroalcoxibenzilamino de heterociclos contendo nitrogénio
TW202432B (de) * 1991-06-21 1993-03-21 Pfizer
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
FI942187L (fi) * 1991-11-12 1994-05-11 Pfizer Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
CA2134964C (en) * 1992-05-18 1997-12-30 Manoj C. Desai Bridged aza-bicyclic derivatives as substance p antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
GB2268931A (en) * 1992-07-22 1994-01-26 Merck Sharp & Dohme Azabicyclic tachykinin-receptor antagonists
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
EP1114823A3 (de) * 1992-08-19 2001-07-18 Pfizer Inc. Substituierte Benzylamin-Stickstoff enthaltende nichtaromatische Heterocyclen
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
US5837711A (en) * 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
US5886009A (en) * 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
IT1271462B (it) * 1993-12-03 1997-05-28 Menarini Farma Ind Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2719476B1 (fr) * 1994-05-05 1997-05-23 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
FR2719474B1 (fr) * 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
AU7247898A (en) * 1997-04-11 1998-11-11 Eli Lilly And Company Composition for treating pain
WO2000010545A2 (en) * 1998-08-25 2000-03-02 Novartis Ag Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
US7101547B1 (en) 1999-01-22 2006-09-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100885986B1 (ko) 1999-11-03 2009-03-03 에이엠알 테크놀로지, 인크. 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도
ATE362926T1 (de) * 2000-01-20 2007-06-15 Eisai R&D Man Co Ltd Stickstoffhaltige cyclische verbindungen und sie enthaltende pharmazeutische zubereitungen
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
AU9042201A (en) 2000-09-20 2002-04-02 Karolinska Innovations Ab 1-azabicyclo(2.2.2)octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
EP1192952A3 (de) * 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
SE0400708D0 (sv) * 2004-03-22 2004-03-22 Aprea Ab New compounds and use thereof
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1888050B1 (de) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
ZA200800440B (en) 2005-07-15 2009-12-30 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (de) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amidsubstituierte Indazole als Poly-(ADP-Ribose)-Polymerase (PARP)-Hemmer
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
EP2429295B1 (de) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl-, heteroaryl- und heterocyclen-substituierte tetrahydroisochinoline und ihre verwendung
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
EP2488028B1 (de) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (de) 2011-04-21 2014-02-26 Piramal Enterprises Limited Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (de) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. Sina-zusammensetzungen
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
WO1992012151A1 (en) * 1991-01-10 1992-07-23 Pfizer Inc. N-alkyl quinuclidinium salts as substance p antagonists

Also Published As

Publication number Publication date
ZA914134B (en) 1993-01-27
CA2084193A1 (en) 1991-12-02
NO924612D0 (no) 1992-11-30
HU9203777D0 (en) 1993-03-29
EP0532527B1 (de) 1994-11-09
JPH05506243A (ja) 1993-09-16
DK0532527T3 (da) 1995-01-02
DE69105131T2 (de) 1995-03-23
KR930700499A (ko) 1993-03-15
US5451586A (en) 1995-09-19
FI925443L (fi) 1992-11-30
PT97771A (pt) 1992-03-31
CA2084193C (en) 1998-04-07
JPH072740B2 (ja) 1995-01-18
DE69105131D1 (de) 1994-12-15
AU7860291A (en) 1991-12-31
WO1991018899A1 (en) 1991-12-12
IE911856A1 (en) 1991-12-04
NO924612L (no) 1992-11-30
AU648317B2 (en) 1994-04-21
IL98259A0 (en) 1992-06-21
FI113654B (fi) 2004-05-31
ES2063507T3 (es) 1995-01-01
EP0532527A1 (de) 1993-03-24
HUT62891A (en) 1993-06-28
FI925443A0 (fi) 1992-11-30

Similar Documents

Publication Publication Date Title
ATE113947T1 (de) 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DE69104723D1 (de) Hustenstillendes und schleimregulierendes mittel, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
DE59109082D1 (de) Mono-N-substituierte 1,4,7,10-Tetraazacyclododecan-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE69307340D1 (de) Chinuclidin derivat als substanz p antagonist
ES2117795T3 (es) Derivados de acetamida y su uso como modificadores del comportamiento de toma alimentaria.
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
ATE152443T1 (de) Anilide-derivate
FI961914A0 (fi) Lyhytvaikutteiset dihydropyridiinit
DK0474712T3 (da) Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat
DE69511544D1 (de) Amidderivate und ihre therapeutische verwendung
ES2175405T3 (es) Derivados de adenosina.
ATE152442T1 (de) Substituierte arylalkylaminobenzyl- aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
DE69103630D1 (de) Oxazolederivate, ihre herstellung und diese enthaltende pharmazeutischen zubereitungen.
DK0720598T3 (da) Phenoxyphenylcyclopentenyl-hydroxyurinstoffer
ES527353A0 (es) Procedimiento de preparacion de nuevos derivados de la nitrosourea
ATE68494T1 (de) Benzofuranderivate und diese enthaltende therapeutische mittel.
ES2138226T3 (es) Derivados del acido imidazo(1,2-a)indeno(1,2-e)pirazina-2-carboxilico, su preparacion y los medicamentos que les contienen.
ES487631A1 (es) Procedimiento para la obtencion de hexahidro-1,4-oxazepinas
KR900002775A (ko) 피라졸로피리딘 유도체의 에테롬성동맥경화증 및 과콜레스테린 혈증 치료 용도
PT73789B (de) Neue cephalosporine verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AR011139A1 (es) 4-aminoalcoxi-1,3-dihidro-benzoimidazol-2-tionas, su uso en la preparacion de un medicamento y composicion farmaceutica que los contiene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee